Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac
- Registration Number
- NCT02180516
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to assess the safety profile of meloxicam by comparing incidence of gastrointestinal adverse events of meloxicam with that of NSAID in the routine daily therapeutic situation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9984
Inclusion Criteria
- Patients with Indications according to the package insert of the prescribed NSAID
Exclusion Criteria
- There is no exclusion criterion, because this Post Marketing Study is an observational study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Other NSAIDs Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac - Meloxicam Meloxicam -
- Primary Outcome Measures
Name Time Method Incidence for adverse event of gastrointestinal disorder up to 6 months
- Secondary Outcome Measures
Name Time Method Incidence for adverse events Perforation, Ulcer and Bleeding (PUB) in the upper gastrointestinal tract up to 6 months Incidence for adverse drug reaction of gastrointestinal disorder up to 6 months Incidence of adverse events up to 6 months Incidence of adverse drug reactions up to 6 months Incidence of serious adverse events up to 6 months